Anti-GAD antibody cerebellar ataxia mimicking multiple system atrophy
Objective: To describe a case of anti-glutamic acid decarboxylase antibody (GAD-Abs)-associated cerebellar ataxia (CA), which presented with gradual dysautonomia and parkinsonism fulfilling criteria for MSA,…Creutzfeldt-Jakob disease presenting predominantly with movement disorder: A case report
Objective: To highlight that Creutzfeldt-Jakob Disease can present predominantly with movement disorder. Background: Creutzfeldt-jakob Disease (CJD) is a rapidly progressive spongioform degeneration of the brain…Objectives of the MDS rare movement disorders study group
Objective: There is a need to unify diagnostic criteria, develop a comprehensive approach regarding educational and practical challenges in diagnosis, treatment, and outcome measures and…Can quantitative analysis of the “finger-to-nose test” discern between EOA and other conditions of coordination impairment?
Objective: In Early Onset Ataxia (EOA), we investigated whether quantitative analysis employing motion sensors could provide reliable and discriminative outcomes. Background: Many pediatric conditions can…Adult onset Niemann-Pick type C: 24 month follow-up on miglustat
Objective: To present a rare case of adult onset NPC patient and pointing out varying response of her distinct symptoms on long term follow up…Burden of movement disorders in Cameroon: In/out patient population study
Objective: To create a registry and surveillance of neurological disease from health care districts in Cameroon from 2012 to 2014. Background: Due to rapid demographic…Predominant motor neuron involvement in autosomal recessive SYNE1 ataxia
Objective: We here report on a novel SYNE1 mutation in an Austrian family extending the classical clinical phenotype in SYNE1 ataxia. Background: SYNE1 codes for…PARK-OMM – An osteopathic manipulative medicine protocol to improve motor function and balance in Parkinson’s disease
Objective: To evaluate the effects of a pre-defined Osteopathic Manipulative Medicine (OMM) treatment protocol (PARK-OMM) for 6 weeks compared to a 6-week controlled counseling period…Topiramate responsive adult-onset opsoclonus myoclonus ataxia syndrome
Objective: Opsoclonus myoclonus ataxia (OMA) is a rare neurological syndrome characterized with with autoimmune background. However the exact pathophysiology is not clear. Most common underlying…Novel variants in the SACS gene in a first Central-Eastern European family with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)
Objective: To present genetics, clinical description and natural history of the disease in four members of a Polish family with novel variants in the SACS…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- 27
- Next Page »